您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > XJB-5-131
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
XJB-5-131
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
XJB-5-131图片
规格:98%
分子量:960.25
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
XJB-5-131 是一种靶向线粒体的 ROS 和电子清除剂。XJB-5-131 是双功能抗氧化剂,包含自由基清除剂。XJB-5-131 是针对线粒体的合成抗氧化剂。XJB-5-131 是有效的脐带血单核细胞 (CB MNC) 电离辐射保护剂和缓和剂。
货号:ajcx37836
CAS:866404-31-1
分子式:C53H81N7O9
分子量:960.25
溶解度:DMSO : 125 mg/mL (130.17 mM; Need ultrasonic)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

XJB-5-131 is a mitochondria-targeted ROS and electron scavenger[1]. XJB-5-131 is a bi-functional antioxidant that comprises a radical scavenger. XJB-5-131 is a synthetic antioxidant that targets mitochondria[2]. XJB-5-131 is an effective ionizing irradiation protector and mitigator of cord blood mononuclear cells (CB MNCs)[3].

XJB-5-131 also ameliorates hemorrhagic shock (HS)-induced activation of the pro-apoptotic enzymes, caspases 3 and 7, in ileal mucosa[1].XJB-5-131 reduces apoptosis and enhances cell survival in mouse embryonic cells in vitro[2].XJB-5-131 is a radiation protector for colony-forming unit-granulocyte macrophage (CFU-GM). XJB-5-131 is an effective mitigator when added after irradiation[3].

XJB-5-131 ameliorates peroxidation of the mitochondrial phospholipid, cardiolipin, in ileal mucosal samples from rats subjected to hemorrhagic shock (HS) [1].Intravenous treatment with XJB-5-131 (2 μmol/kg) significantly prolongs the survival of rats subjected to profound blood loss (33.5 mL/kg) despite administration of only a minimal volume of crystalloid solution (2.8 mL/kg) and the absence of blood transfusion[1].XJB-5-131 reduces oxidative damage to mitochondrial DNA, maintains mitochondrial DNA copy number, suppresses motor decline and weight loss, enhances neuronal survival, and improves mitochondrial function. XJB-5-131 significantly suppresses the disease phenotypes and improves mitochondrial function in a mouse model of Huntington's disease (HD) [2].XJB-5-131 (1 mg/kg; intraperitoneally injected; three times a week up to 57 weeks) suppresses decline of weight loss and motor function in a mouse model of HD[2].

[1]. Carlos A Macias, et al. Treatment with a novel hemigramicidin-TEMPO conjugate prolongs survival in a rat model of lethal hemorrhagic shock. Ann Surg. 2007 Feb;245(2):305-14.
[2]. Zhiyin Xun, et al. Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease. Cell Rep. 2012 Nov 29;2(5):1137-42.
[3]. Julie P Goff, et al. Evaluation of potential ionizing irradiation protectors and mitigators using clonogenic survival of human umbilical cord blood hematopoietic progenitor cells. Exp Hematol. 2013 Nov;41(11):957-66.